Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristine Broglio

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
The Oncologist|September 4, 2007
Trends for inflammatory breast cancer: is survival improving?Ana M Gonzalez-Angulo, Bryan T Hennessy, Kristine Broglio, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2012
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemiaKhanh Vu, Naifa Busaidy, Maria E Cabanillas, et al.
Cancer|April 28, 2006
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 yearsEmer O Hanrahan, Kristine Broglio, Deborah Frye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomesShaheenah Dawood, Kristine Broglio, Shu-Wan Kau, et al.
Leukemia & Lymphoma|July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial designKristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancerCatherine M Kelly, Marjorie C Green, Kristine Broglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.
International Journal of Cancer|May 12, 2020
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastomaElizabeth C Lewis, Jacqueline M Kraveka, William Ferguson, et al.
The Oncologist|November 2, 2011
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term resultsBanu K Arun, Kapil Dhinghra, Vicente Valero, et al.
BMJ Open|April 3, 2023
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injuryPeter Pickkers, Derek C Angus, Jacques Arend, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
The Oncologist|September 4, 2007
Trends for inflammatory breast cancer: is survival improving?Ana M Gonzalez-Angulo, Bryan T Hennessy, Kristine Broglio, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2012
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemiaKhanh Vu, Naifa Busaidy, Maria E Cabanillas, et al.
Cancer|April 28, 2006
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 yearsEmer O Hanrahan, Kristine Broglio, Deborah Frye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomesShaheenah Dawood, Kristine Broglio, Shu-Wan Kau, et al.
Leukemia & Lymphoma|July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial designKristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancerCatherine M Kelly, Marjorie C Green, Kristine Broglio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.
International Journal of Cancer|May 12, 2020
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastomaElizabeth C Lewis, Jacqueline M Kraveka, William Ferguson, et al.
The Oncologist|November 2, 2011
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term resultsBanu K Arun, Kapil Dhinghra, Vicente Valero, et al.
BMJ Open|April 3, 2023
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injuryPeter Pickkers, Derek C Angus, Jacques Arend, et al.
Pageof 10